These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The "tone at the top": can it mitigate C-suite personal liability? Page GV; Waring MA; Kaiser GR; Cornish K Food Drug Law J; 2008; 63(3):723-34. PubMed ID: 19031671 [No Abstract] [Full Text] [Related]
27. The policy outlook from the Hill. Vastag B Nat Biotechnol; 2007 Jan; 25(1):13-6. PubMed ID: 17211381 [No Abstract] [Full Text] [Related]
28. Canadian perspectives on expectations for process validation. Ridgway A Dev Biol (Basel); 2003; 113():3-8. PubMed ID: 14620846 [No Abstract] [Full Text] [Related]
29. Four rebuffs for Cabilly. Waltz E Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392001 [No Abstract] [Full Text] [Related]
30. Growing pains. Merger leaves two reprocessors to withstand congressional scrutiny. Mantone J Mod Healthc; 2006 Jan; 36(2):17. PubMed ID: 16447362 [No Abstract] [Full Text] [Related]
31. Purchasers beware. Better oversight of foreign pharma plants just the first step. Alkire M Mod Healthc; 2009 Jun; 39(22):19. PubMed ID: 19522196 [No Abstract] [Full Text] [Related]
32. A nail in the coffin for DNA sequence patents? Yamanaka M Nat Biotechnol; 2008 Oct; 26(10):1085-6. PubMed ID: 18846072 [No Abstract] [Full Text] [Related]
33. Are insurers getting too big? Lowes R Med Econ; 2004 Oct; 81(19):18, 20. PubMed ID: 15554099 [No Abstract] [Full Text] [Related]
35. No relaxing for relators: Stringent pleading requirements result in frequent dismissal of FCA claims for off-label marketing. Clark JC; Sullivan JA Health Care Law Mon; 2009 Mar; 2009(3):2-9. PubMed ID: 19388590 [No Abstract] [Full Text] [Related]
36. The pharmaceutical industry at risk: how excessive government regulation stifles innovation. Epstein RA Clin Pharmacol Ther; 2007 Aug; 82(2):131-2. PubMed ID: 17632536 [TBL] [Abstract][Full Text] [Related]
37. Pharma to boycott UK? Mitchell P Nat Biotechnol; 2008 Aug; 26(8):847. PubMed ID: 18688226 [No Abstract] [Full Text] [Related]
39. Pa.: keep 'em separated. Blues merger rejection could have wider implications. Vesely R Mod Healthc; 2009 Jan; 39(4):10. PubMed ID: 19213127 [No Abstract] [Full Text] [Related]
40. Feds OK Pa. Blues merger ... but state approval promises to be more difficult. Becker C Mod Healthc; 2007 Jun; 37(23):10. PubMed ID: 17612001 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]